HIV 1 News and Research

RSS

Metabolic restoration as a therapeutic approach to promote natural immune protection against HIV

The human immunodeficiency virus (HIV-1) particularly attacks CD4 lymphocytes, a type of white blood cell considered to be the conductor of the immune system.

15 Oct 2021

Research reveals components of Sinbis virus ribonucleoproteins

To address this gap in research regarding the understanding of post-replicative alphavirus RNPs, scientists have created a novel proteome-wide approach known as viral RNA interactome capture (vRIC). This study is available in the bioRxiv* preprint server while awaiting peer review.

11 Oct 2021

Research finds different antibody responses following COVID vaccination and natural infection

A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth.

10 Oct 2021

Researchers identify new biomarker for severe COVID-19

During the pandemic, it has become increasingly evident that people with cardiovascular disease and obesity are at a much higher risk of developing very severe, even fatal COVID-19 disease.

8 Oct 2021

Potent extended anti- SARS-CoV-2 effect of titanium dioxide surface coatings

A team of researchers has explored the possibility of coating surfaces with TiO2 as a tool to inactivate SARS-CoV-2.

7 Oct 2021

Critical function of IL-7 in diagnosis, prognosis, and treatment of COVID-19 patients

In this review, researchers summarized the therapeutic and pathogenic role of IL-7 in patients with COVID-19 and examined the promising role of IL-7 as a vaccine adjuvant.

7 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Hyperbranched polylysine nanopolymer as potential broad-spectrum antiviral against SARS-CoV-2

The findings from this study suggest that HPNs may inhibit viral replication and budding.

27 Sep 2021

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

New research suggests SARS-CoV-2 spike protein substitution mutations can create a replication-defective viral particle that makes the virus resistant to vaccine-induced antibodies.

23 Sep 2021

Temple research paves the way for first Phase 1/2 clinical trials of CRISPR-based therapy for HIV

For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University have been developing and refining CRISPR-based gene-editing technology for the treatment of human immunodeficiency virus type 1 (HIV) infection.

17 Sep 2021

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Self-amplifying RNA (saRNA) is an advanced platform for nucleic acid vaccine development. The backbone is typically derived from an alphaviral genome and encodes a gene of interest (GOI) and a viral replicase that can amplify the genomic and subgenomic RNA.

30 Aug 2021

COVID booster shots might be needed in subgroup of HIV-positive individuals

The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic destroying lives and economies. COVID-19 is not curable, so vaccines are the only safeguard during this pandemic.

23 Aug 2021

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

A new study finds that human gut bacteria can induce antibodies of the immunoglobulin A (IgA) subtype that cross-react with the SARS-CoV-2 spike RBD.

15 Aug 2021

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Researchers in the United States have conducted a study showing the difference in antibody evolution following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between people who have not previously been infected with the virus and those who have.

1 Aug 2021

Antiviral activity of long-chain polyphosphates against SARS-CoV-2 infection

A new study has been published in Science Signaling that has examined the potential role that long-chain inorganic polyphosphates (polyPs) play against SARS-CoV-2 infection.

9 Jul 2021

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

In a recently published article scientists have provided a detailed description of the utility of mannose-specific lectins in preventing coronavirus infections. They have specifically explained how mannose-specific lectins derived from plants, algae, fungi, and bacteria selectively bind N-glycans present on the surface of viral spike protein and how such interactions can be medically utilized to control coronavirus transmission.

1 Jul 2021

New biomarkers can predict HIV remission after antiretroviral therapy interruption

New biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are critical for the development of new therapeutic strategies that can achieve infection control without ART, a condition defined as functional cure.

29 Jun 2021

Indian SARS-CoV-2 variant has unique infection and immune escape strategy say researchers

Researchers have conducted a study suggesting that the B.1.617 lineage of SARS-CoV-2 that emerged in India has evolved a unique strategy.

23 Jun 2021

Texas Biomed scientists receive $1 million NIH funding for Ebola research

Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus.

18 Jun 2021

Carbon-based antimicrobial nanoweapons to fight COVID-19

In a recent review article published in the journal ACS Nano, interdisciplinary researchers from across the world evaluated the role of carbon-based nanomaterials (CBNs), such as fullerene, carbon dots, graphene, and their derivatives as promising alternatives to combat COVID-19 (coronavirus disease 2019) and other microbial infections.

15 Jun 2021